Suppression of craving and other signs of dependence in morphine-addicted monkeys by administration of alpha-methyl-para-tyrosine.
D000818:Animals; D005260:Female; D010134:Fenclonine / Q000008:administration & dosage / Q000627:therapeutic use; D006220:Haloperidol / Q000008:administration & dosage / Q000627:therapeutic use; D000882:Haplorhini; D006801:Humans; D007031:Hypothalamus / Q000502:physiology; D007275:Injections, Intravenous; D008251:Macaca; D008691:Methadone / Q000008:administration & dosage / Q000627:therapeutic use; D008781:Methyltyrosines / Q000008:administration & dosage / Q000627:therapeutic use*; D009020:Morphine / Q000008:administration & dosage; D009269:Nalorphine / Q000008:administration & dosage; D012686:Septal Nuclei / Q000502:physiology; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy; D019966:Substance-Related Disorders / Q000188:drug therapy*; D013881:Thioridazine / Q000008:administration & dosage / Q000627:therapeutic use; D014268:Trifluoperazine / Q000008:administration & dosage / Q000627:therapeutic use
D008781:Methyltyrosines; D014268:Trifluoperazine; D009020:Morphine; D006220:Haloperidol; D013881:Thioridazine; D010134:Fenclonine; D009269:Nalorphine; D008691:Methadone